Granite Point Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Granite Point Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-110,000	Closed	-$4.12M	–	90
2016 Q4	$4.12M	Buy	+110,000	New	+$4.61M	3.28%	7
2015 Q4	–	Sell	-3,708	Closed	-$298K	–	84
2015 Q3	$298K	Sell	3,708 -162	-4%	-$18K	0.2%	73
2015 Q2	$464K	Sell	3,870 -1,130	-23%	-$135K	0.14%	75
2015 Q1	$522K	Hold	5,000	–	–	0.19%	75
2014 Q4	$485K	Buy	+5,000	New	+$463K	0.23%	63

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Granite Point Capital Management's ALNY Position: Q1 2017 in Review

Granite Point Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2017, closing a stake of 110,000 shares — an estimated $4.12M sold.

Granite Point Capital Management first reported a position in ALNY in Q4 2014 and held it in 5 quarters. The position peaked at $4.12M in Q4 2016. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

Granite Point Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Granite Point Capital Management sold 110,000 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $4.12M.
Granite Point Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Granite Point Capital Management's Alnylam Pharmaceuticals position peaked at $4.12M in Q4 2016.
199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Granite Point Capital Management's 13F filing for Q1 2017, filed 10 May 2017.